Related posts

This Week’s Stock Picks & BNN Top Picks Summary: IBKR-Q, TOI-X and 21 Stock and 3 ETF Top Picks (Apr 05-11)
Investor Insights

This summary was created by AI, based on 4 opinions in the last 12 months.

EssilorLuxottica (ESLOY-OTC) is a leading player in the eyewear industry, with a strong focus on both technological innovation and fashion. The company benefits from the increasing need for glasses due to prolonged screen time and an aging population. Its recent acquisition of Grand Vision is expected to have a significant impact on its future business. With a solid yield and positive analyst price targets, the stock presents an appealing investment opportunity.

Consensus
Positive
Valuation
Undervalued
Similar
Safilo SPA, SAFLY-OTC
TOP PICK

Glasses and frames. Fashion statement plus necessity. Need has gone up as people age and with increased screen use. Grant purchase gave them huge retail presence. Lots of third-party contracts. Tech leader. Large player among a small group. Yield is 1.6%.

Healthcare
TOP PICK

Lenses plus frames. Lots of third-party business for the likes of Gucci and Armani. Demographic play, plus a fashion play. Screen time has increased need for glasses earlier. Yield is 1.6%.

(Analysts’ price target is $119.37)
Healthcare
TOP PICK

So much screen time is deteriorating people's eyesight, so they need glasses. Aging population needs glasses. Fashion statement. Way ahead on technology. Yield is 1.8%.

(Analysts’ price target is $109.40)
Healthcare
TOP PICK

Lenses plus frames. Has a lock on the whole value chain. Purchase of Grant Vision will dramatically change its business over the next several years. Use of lenses has increased because of aging demographics plus faster eye deterioration from computer screens. Also a fashion statement. Great technology. Yield is 1.7%.

(Analysts’ price target is $109.40)
Healthcare
PAST TOP PICK
(A Top Pick Jun 29/22, Up 23%)

Great growth from a demographic point of view. Largest player in the world in this area. Almost like an oligopoly, especially in making lenses. Really good lens technology, very innovative. Great story. Buy here and still do well.

Healthcare
PAST TOP PICK
(A Top Pick Sep 30/21, Down 19%) A global leader in design, manufacturing and distribution of eyeglasses as well as frames and has a high market share. Eye wear has an attractive long term growth profile. It is clear where management is heading.
Healthcare
PAST TOP PICK
(A Top Pick Aug 24/21, Down 19%) It is a leader in the design, manufacturing and distribution of lenses, frames and sunglasses. Has a great balance sheet and should have good growth for the next few years. It acquired Grand Vision, mostly European, which changed the dynamics of the company and helps them to have a broader digital component. Has a 2.3% dividend.
Healthcare
PAST TOP PICK
(A Top Pick Jul 22/21, Down 11%) Whole spectrum of eyewear business. Screen time has increased demand for kids' eyewear. Demographic play for older adults. Balance sheet getting better. Designer brands. Corporate governance improved.
Healthcare
TOP PICK
price target N/A The global leader in optical frames, lens and sunglasses. The eyewear business is long-term resilient and will grow. A great demographic play, too. Over the last two years, screen use has soared and has caused a lot of eye problems. They bought Grand Vision, which is transformational in a digital way. Pays a 2.3X dividend. Strong balance sheet and cash flow growth will rise.
Healthcare
PAST TOP PICK
(A Top Pick May 07/21, Up 14%) Believes company is in process of optimization previous mergers. Covid-19 pandemic has had adverse affect on company, which created a good buying opportunity. As economy re-opens the company will do well. Continues to own the stock.
Healthcare
TOP PICK
Designer, manufacturer, and distributor of lenses, frames, and sunglasses. Market leader. Huge retail presence in Europe and NA. Really strong growth. Strong online presence. Recent acquisition will be transformational. Great story at these levels. Yield is 0.66%.
Healthcare
TOP PICK
Price target: 169.22 Euros A merger of a French lens company and an Italian frame company, including brands Ray Banz, Chanel, Prada and Oakley, The lens business is stable and amounts to 66% of their revenues. The merger wasn't easy, but he expects $500 million in cut costs. They bought Grand Vision, and its 7,000 European stores to make them a major player in lenses and frames. Now, their online sales are nearly #1 in this space. The only business where they lack are contact lenses. ESLOY is well-integrated, with many of their businesses #1 in their categories. There's a trend of people needing glasses because of looking at TV and computer screens.
Healthcare
TOP PICK

Largest global designer, manufacturer, distributor of lenses in the world. Also does frames and sunglasses. These businesses are resilient and have strong growth going forward. Owns franchises such as LensCrafters and Ray-Ban. GrandVision acquisition will be important. Great balance sheet. Yield is 0.71%.

Healthcare
TOP PICK
Merger of the largest lense maker Essilor with the almost monopolistic maker of eyeware frames Luxotica. Together it is a behemoth. They dominate the market and is also the biggest retailer of eyecare with Pearlvision, LenseCrafters, SunglassHut. Huge in sunglasses too. A return to normal stock. (Analysts’ price target is $179.18)
Healthcare
Showing 1 to 14 of 14 entries
  • «
  • 1
  • »

EssilorLuxottica(ESLOY-OTC) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for EssilorLuxottica is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

EssilorLuxottica(ESLOY-OTC) Frequently Asked Questions

What is EssilorLuxottica stock symbol?

EssilorLuxottica is a American stock, trading under the symbol ESLOY-OTC on the US OTC (ESLOY). It is usually referred to as OTC:ESLOY or ESLOY-OTC

Is EssilorLuxottica a buy or a sell?

In the last year, 1 stock analyst published opinions about ESLOY-OTC. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for EssilorLuxottica.

Is EssilorLuxottica a good investment or a top pick?

EssilorLuxottica was recommended as a Top Pick by on . Read the latest stock experts ratings for EssilorLuxottica.

Why is EssilorLuxottica stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is EssilorLuxottica worth watching?

1 stock analyst on Stockchase covered EssilorLuxottica In the last year. It is a trending stock that is worth watching.

What is EssilorLuxottica stock price?

On 2024-04-12, EssilorLuxottica (ESLOY-OTC) stock closed at a price of $107.3625.